New oral antifungal drug introduced by Hengrui for $110 million approved for clinical trial in China

Author: On May 20,, Hengrui Class 1 new drug SHR8008 capsules were approved for clinical treatment in China for the treatment of recurrent vulvar vaginal fissy (RVVC)The drug is a new oral antifungal drug that Hengrui introduced from Mycovia in June 2019 for $110 millionSHR8008 (VT-1161) is a new oral small molecule selective fungus CYP51 inhibitor developed by Mycovia, which is significantly better selective than the existing commonly used antifungal antifungal drugsJune 2019, Hengrui Pharmaceuticals and Mycovia reached an agreement to introduce Mycovia to treat and prevent a wide range of fungal infections, including recurrent vulvar candida, invasive fungal infections and a myogal diseases of the patented pilot compound VT-1161 (also known as Oteseconaee), which hengrui will receive exclusive rights for clinical development, registration, production and marketing of the compound in Chinaagreement provides that Hengrui acquires an exclusive interest in the clinical development, registration, production and marketing of VT-1161 in the permitted region, i.ethe People's Republic of China (including mainland China, Hong Kong, Macau and Taiwan)Licensed indications are available for the treatment and prevention of all human and animal diseases and symptoms, including but not limited to recurrent vulvar candidiasis, myogal disease and invasive fungal infectionsfinancial terms, Henri will pay Mycovia a total of $7.5 million in research and development payments, as well as up to $9 million in research and development and listing milestone payments and sales milestone payments of up to $92 million and a certain sales commission